A Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Efficacy and Safety of STG320 Sublingual Tablets of House Dust Mite (HDM) Allergen Extracts in Adults and Adolescents With HDM-associated Allergic Rhinitis

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Efficacy and Safety of STG320 Sublingual Tablets of House Dust Mite (HDM) Allergen Extracts in Adults and Adolescents With HDM-associated Allergic Rhinitis

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 03 Oct 2017

At a glance

  • Drugs S 524101 (Primary)
  • Indications Allergic rhinitis
  • Focus Registrational; Therapeutic Use
  • Sponsors Stallergenes Greer plc; Stallergenes SA
  • Most Recent Events

    • 26 Sep 2017 According to a Stallergenes Greer plc media release, this study together with other clinical data, will form the clinical submission of a Biologics License Application (BLA) in the United States currently planned for 2019, as well as for additional marketing authorizations in European and international markets.
    • 25 Jul 2017 Status changed from recruiting to active, no longer recruiting.
    • 19 Jan 2017 Planned End Date changed from 1 Feb 2017 to 1 Apr 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top